Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 27.7% in September

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 18,000 shares, an increase of 27.7% from the August 31st total of 14,100 shares. Based on an average daily trading volume, of 7,900 shares, the short-interest ratio is currently 2.3 days. Approximately 0.2% of the company’s stock are sold short.

Anebulo Pharmaceuticals Stock Down 2.6 %

ANEB traded down $0.05 on Friday, reaching $1.91. The company had a trading volume of 3,512 shares, compared to its average volume of 6,844. Anebulo Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $3.61. The stock has a market capitalization of $49.53 million, a PE ratio of -5.30 and a beta of -1.01. The stock has a 50-day moving average price of $2.05 and a 200-day moving average price of $2.35.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.08. As a group, analysts expect that Anebulo Pharmaceuticals will post -0.48 earnings per share for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.